NeuroPace, Inc. (NPCE)

Market Cap	385.84M
Revenue (ttm)	79.91M
Net Income (ttm)	-27.14M
Shares Out	32.56M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	163,120
Open	12.32
Previous Close	12.38
Day's Range	11.77 - 12.47
52-Week Range	5.45 - 15.78
Beta	2.07
Analysts	Buy
Price Target	14.83 (+25.15%)
Earnings Date	Mar 4, 2025

About NPCE

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In ad...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 22, 2021
• Employees: 184
• Stock Exchange: NASDAQ
• Ticker Symbol: NPCE
• Website: https://www.neuropace.com

Financial Performance

In 2024, NeuroPace's revenue was $79.91 million, an increase of 22.14% compared to the previous year's $65.42 million. Losses were -$27.14 million, -17.64% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for NPCE stock is "Buy." The 12-month stock price forecast is $14.83, which is an increase of 25.15% from the latest price.

Price Target

$14.83

(25.15% upside)

Analyst Consensus: Buy